Herpes Zoster News and Research

RSS

Herpes Zoster, also called shingles, is a painful skin rash caused by the varicella-zoster virus, the same virus that causes chickenpox. After a person recovers from chickenpox, the virus remains inactive in the body. Usually the virus does not cause any further problems; however, the virus may re-emerge years later, causing shingles.

Study on bacterial infection in older individuals

The older population is prone to microbial infections, which can lead to death. Hence, it is important to understand why this group is vulnerable to microbial infection, especially bacterial infection. A recent Scientific Reports study linked data from two sources to understand the determining factors for microbial infection in the older population in the UK.

11 Jan 2023

Shingles linked with higher long-term risk of major cardiovascular event

A new study by investigators from Brigham and Women's Hospital, a founding member of the Mass General Brigham healthcare system, demonstrated that shingles, also known as herpes zoster, is associated with an almost 30% higher long-term risk of a major cardiovascular event such a stroke or heart attack.

22 Nov 2022

New EULAR recommendations for screening and treating infections in AIIRD patients

It is already known that people who are immunocompromised are more prone to infections. Chronic and opportunistic infections are often found in people with an AIIRD, and may be linked to some of the immunosuppressive and immunomodulatory treatments used to treat these rheumatic diseases.

22 Nov 2022

CU Anschutz study details the mechanisms behind the link between shingles and strokes

Scientists investigating why people who have had shingles are at a higher risk of stroke, now believe the answer lies within lipid vesicles called exosomes that shuttle proteins and genetic information between cells, according to new research from the University of Colorado Anschutz Medical Campus.

28 Oct 2022

25 years on, varicella vaccination reports impressive success in the USA

New research suggests that 25 years on, varicella vaccination continues to report impressive success in the USA.

26 Oct 2022

IRIS Registry presents latest eye research at AAO 2022

The IRIS Registry (Intelligent Research in Sight) powered several big data studies this year, most of which will be presented and discussed at AAO 2022 Gather, the 126th annual meeting of the American Academy of Ophthalmology.

30 Sep 2022

COVID-19 booster shots essential for maintaining long-term immunity against infection in older adults

In a study of more than 80 men and women from Baltimore, Maryland, Johns Hopkins researchers have added to evidence that COVID-19 booster shots are essential for maintaining long-term immunity against infection, particularly among older adults.

29 Sep 2022

How effective are live-attenuated SARS-CoV-2 vaccines?

Researchers opined on the use of live-attenuated whole virus vaccines as COVID-19 vaccines.

26 Sep 2022

RINVOQ® (upadacitinib) Approved by European Commission as an Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis

With this approval, RINVOQ® is the first and only Janus Kinase inhibitor approved to treat patients across the spectrum of axial spondyloarthritis (nr-axSpA and ankylosing spondylitis) in the EU.

From AbbVie 29 Jul 2022

CDC’s activation of Emergency Operations Center helps improve the response to monkeypox outbreak

Today, CDC continues to lean forward with an aggressive public health response to the monkeypox outbreak by activating its Emergency Operations Center (EOC).

1 Jul 2022

CHMP recommends approval of upadacitinib (RINVOQ®) for the treatment of adults with active non-radiographic axial spondyloarthritis

AbbVie today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of upadacitinib (RINVOQ® 15 mg, once daily) for the treatment of active non-radiographic axial spondyloarthritis (nr‑axSpA) in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).*

27 Jun 2022

Study evaluates the prevalence of autoantibodies targeting type I interferons in critically-ill COVID-19 patients

Researchers assessed the prevalence of antibodies that neutralize the type I interferon antiviral activity and reactivate herpesviruses such as herpes simplex virus types 1 and 2 and/or cytomegalovirus infections in patients with critical COVID-19.

24 Mar 2022

Dreaded microbe can silence multiple types of pain, study suggests

Anthrax has a scary reputation. Widely known to cause serious lung infections in humans and unsightly, albeit painless, skin lesions in livestock and people, the anthrax bacterium has even been used as a weapon of terror.

20 Dec 2021

Large Israeli study offers detailed look at safety profile of mRNA vaccine against SARS-CoV-2

A deep look into a nationwide mass vaccination setting in Israel revealed that the BNT162b2 (Pfizer–BioNTech) vaccine is not linked with an elevated risk of a majority of the adverse events under study, with the exception of myocarditis. However, even that potentially severe adverse event is much more pervasive following the infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), found a new study published in the New England Journal of Medicine (NEJM).

30 Aug 2021

Study examines safety of COVID-19 vaccine in a nationwide mass-vaccination setting

The Clalit Research Institute, in collaboration with researchers from Harvard University, analyzed one of the world's largest integrated health record databases to examine the safety of the Pfizer/BioNTech BNT162B2 vaccine against COVID-19.

27 Aug 2021

How can COVID-19 affect the skin?

A new review published in the journal Canadian Family Physician describes skin diseases caused by the coronavirus disease 2019 (COVID-19).

20 Aug 2021

mRNA COVID-19 vaccines may increase patients' concerns about side effects

Vivid photos of the red "COVID arm" rash and reports of facial swelling in patients who have received dermatological fillers after Pfizer-BioNTech or Moderna vaccination for COVID-19 may increase patients' concerns about mRNA vaccine side effects and contribute to vaccine hesitancy.

23 Jun 2021

Vaccines can save lives and safeguard health and well-being

Effectively and safely protecting against disease--this is what makes vaccines a vital and successful public health tool that saves lives and safeguards health and well-being. Today, vaccines shield us from more than 20 life-threatening diseases.

30 Apr 2021

Despite all the talk, Covid vaccination does not infect people with shingles

Posts are showing up all over social media tying Covid-19 vaccinations to shingles and other painful skin disorders.